Continuous Noninvasive Blood Pressure Patents: Leaders & Gaps 2026
- 78.3% concentration. The top 5 assignees account for 18 of the 23 records in scope — a field with a clear head and a thin tail.
- Flat, not falling, filing. Filing held at 0% growth from 2021 to 2024; 2025–2026 figures are still filling in as publication lags filing by roughly 18 months.
- Single IPC anchor. Every record in scope carries A61B (diagnosis & surgery); only one record ventures into H02K, leaving almost no cross-class diversification.
Filing growth compares 2021 (1 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 23 records in scope (CR5), not by the ranked leaders only.
What the patent record shows
Continuous noninvasive blood pressure monitoring covers methods that estimate arterial pressure without a cuff — pulse transit time, volume clamp technique and related waveform-derived approaches — validated against arterial line or auscultatory reference standards. The scope here is defined tightly around calibration interval, motion artefact handling and validation protocol claims, which is why the record count is modest: 23 published records between 2015 and 2026.
That small denominator matters for how the numbers should be read. A handful of filings can swing a percentage sharply, and the concentration at the top is real rather than a statistical artefact — one assignee alone accounts for 6 of the 23 records.
Filing trend and technology composition
Two views of the same 23-record dataset: activity over time, and how records distribute across IPC subclasses.
Filing trend, 2017–2026
Filings peaked in 2022 at 3 records. Growth from 2021 to 2024 sits flat at 0%, and the 2025–2026 tail is understated because publication lags filing by roughly 18 months — treat the most recent two years as incomplete rather than as a slowdown.
IPC subclass distribution
A61B (diagnosis & surgery) touches all 23 records in scope — essentially the entire field files under this single subclass. H02K (electric motors & generators) appears in just 1 record, a marginal secondary class rather than a genuine second technology cluster.
Shares are the percentage of the 23 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Continuous Noninvasive Blood Pressure Monitoring with Eureka
This page is one run against one query. Ask Eureka your own question about continuous noninvasive blood pressure monitoring and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
WO2024260375A1 — Single-point radial artery pulse wave cuffless blood pressure detection device and wearable device
Filed by Tsinghua University, this application describes a wearable cuffless blood pressure device built around a single-point radial artery pulse sensor, an analogue-to-digital conversion unit, and a microprocessing control unit that runs the digitised pulse waveform through a cuffless blood pressure detection model to derive a blood pressure value. The terminal device layer adds AI analysis of continuous waveform and pressure changes, waveform display, health reporting and early-warning alerts.Abstract translated and condensed from the original filing for readability.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20230284916A1 | Continuous noninvasive blood pressure measurement | 203 |
| 2 | WO1995013014A1 | Continuous noninvasive blood pressure monitoring system | 20 |
| 3 | US9820696B1 | Cuffless blood pressure measurement using handheld device | 18 |
| 4 | US20250302426A1 | Continuous noninvasive blood pressure measurement | 17 |
| 5 | US20160353998A1 | Apparatus and method for noninvasive and cuffless blood pressure measurement | 16 |
| 6 | US20230200668A1 | Methods, systems and machine readable programs for cuffless blood pressure measurement | 15 |
| 7 | US20180035949A1 | Cuffless Blood Pressure Measurement Using Handheld Device | 8 |
| 8 | US20240138687A1 | Cuffless Blood Pressure Measurement Apparatus and Method | 3 |
| 9 | US11666230B1 | Electronic device and method for noninvasive, continuous blood pressure monitoring | 2 |
| 10 | — | Apparatus and method for noninvasive and cuffless blood pressure measurement | 2 |
Citation counts reflect a searched corpus and favour older filings; treat them as a measure of influence within this set, not of current commercial importance.
Publication numbers are shown where the record carries one (9 of 10 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three read-outs from the dataset that matter more than the headline counts.
The field has a head, not a spread
18 of the 23 records in scope sit with five assignees, and the leader alone holds 6. A newcomer is not entering a fragmented space — freedom-to-operate work should start with the leader's claim set, not a broad landscape scan.
Activity is flat, not accelerating
The three-year span from 2021 to 2024 — the last period with complete publication data — shows no net growth. Read the 2025–2026 dip as incomplete data, not as declining interest.
Nearly everything files under one class
Every record in scope is tagged A61B; only a single record extends into H02K. That leaves the claim space almost entirely defined by diagnostic and surgical framing, with no meaningful secondary cluster to diversify into.
Influence is skewed to a handful of documents
The most-cited record in this set draws 203 citations, an order of magnitude above the rest of the table. That concentration of citations in a searched corpus typically signals foundational method claims rather than recent activity.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous noninvasive blood pressure monitoring, with the prior art for and against each one.
Who holds the claims, and what is still open
The ranked leaders in this dataset span established diagnostics manufacturers, individual inventors and university filers — a mix that suggests the core waveform-based methods are locked up while device-level and validation claims remain more accessible.
One assignee anchors the field
The top-ranked assignee holds 6 of the 23 records, roughly a quarter of everything published in this scope. Their co-assignee pairs recur across multiple filings, pointing to a sustained internal programme rather than a single opportunistic filing.
A thin band beneath the leader
Filing drops sharply after the leader — fifth place holds just 1 record, the same as tenth place. That gap between the top and everyone else is the clearest sign that later entrants have filed narrowly rather than building portfolios.
Momentum has cooled across the board
Every assignee tracked for recent-year momentum shows zero filings in the latest year, including a -100% year-on-year swing for one major diagnostics player. This is consistent with the 18-month publication lag rather than an actual halt in R&D.
| Assignee | Recent year | YoY |
|---|---|---|
| Medwave Inc | 0 | — |
| Masimo Corp | 0 | -100% |
| National Central University | 0 | — |
| NARASIMHAN RAVI | 0 | — |
| Tsinghua University | 0 | — |
| THEDE ROGER C | 0 | — |
| SPARKS DOUGLAS | 0 | — |
| RUIZ GRACIELA AURORA | 0 | — |
Where to take this analysis
The dataset points to a narrow but well-defended core. The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying a filing gap.
Map the leader's full claim set
With 6 of 23 records and repeated co-assignee pairs, the top-ranked filer's claims are the first thing to clear before committing engineering resources to pulse transit time or volume clamp approaches.
Explore assignee claims in EurekaTest white space claims before filing
The under-claimed sub-areas above are candidates for a first claim, but each needs checking against the most-cited records individually, since citation concentration suggests foundational prior art may already cover adjacent method steps.
Run a claim-gap check in EurekaCommon questions on this landscape
Filing in this dataset is concentrated: the top-ranked assignee holds 6 of the 23 records in scope, and the top 5 assignees combined account for 78.3% of all records. Beyond that group, filing drops off quickly — fifth place and tenth place each hold just 1 record. This pattern means a competitive review should focus first on the leader's claim family before scanning the long tail of single-filing entrants.
Filing activity was flat between 2021 and 2024, the last period with complete publication data, at 0% growth. The apparent dip in 2025–2026 is not a real slowdown; publication typically lags filing by roughly 18 months, so recent-year counts are always understated. The peak year on record so far is 2022, with 3 filings.
Essentially the entire dataset — all 23 records in scope — carries the IPC subclass A61B, which covers diagnosis and surgery. Only one record extends into H02K, electric motors and generators, likely reflecting a device with a motorised or actuated component. This means the field is defined almost entirely by a single classification lens rather than spreading across multiple technical disciplines.
WO2024260375A1, filed by Tsinghua University, describes a wearable cuffless blood pressure device that captures a single-point radial artery pulse waveform, digitises it, and runs it through a cuffless blood pressure detection model to derive a pressure value, with an AI analysis and reporting layer on the terminal device. It is a representative record in this dataset rather than the single most-cited one. Anyone building a single-sensor wearable pressure estimation product should review its specific claim scope, particularly around the single-point sensing and model-based inference steps.
Based on the class and citation concentration in this dataset, under-claimed areas include wearable single-point waveform sensing, AI-driven waveform-to-pressure inference models, long-interval self-calibration methods, motion artefact rejection tuned for ambulatory use, and standardised cross-device validation protocols. These are candidates rather than guarantees of open space — each needs individual checking against the most-cited records, since a small dataset can still hide broad foundational claims.
Research Continuous Noninvasive Blood Pressure Monitoring in depth with Eureka
Go past this page: query the whole continuous noninvasive blood pressure monitoring corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.